Roche targets cancer vaccine partnerships

Roche ($RHHBY) is looking to ink cancer vaccine partnerships as part of the new strategy at its early development group, an executive told FierceBiotech. The interest in vaccine deals stems from a belief that tweaking the immune system can have a major impact on cancer care. Interview

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.